Zanidatamab Combo Appears ‘Exciting’ in HER2+/HR+ Metastatic Breast Cancer
January 25th 2024High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
ctDNA May Predict Chemo Efficacy in Stage II/III Colorectal Cancer
January 21st 2024Disease-free survival benefits with chemotherapy appears to be more prominent in patients with colorectal cancer who are minimal residual disease–positive compared with those minimal residual disease–negative disease.